ANTX

AN2 Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with significant unmet medical needs. Headquartered in Menlo Park, California, the company's lead product candidate is epetraborole, a novel boron-based antibiotic designed to inhibit bacterial protein synthesis through a unique mechanism of action. Epetraborole is currently in clinical development for Mycobacterium avium complex (MAC) lung disease, a difficult-to-treat pulmonary infection that primarily affects immunocompromised patients and those with underlying lung conditions. The company is conducting Phase 2 clinical trials evaluating epetraborole both as a standalone therapy and in combination with standard-of-care treatments for MAC lung disease. AN2 Therapeutics went public in October 2021 through an initial public offering that raised approximately $151 million. The company's development strategy focuses on leveraging epetraborole's differentiated mechanism to address bacterial infections where current treatment options are limited by drug resistance, poor tolerability, or lengthy treatment durations. As of its recent filings, AN2 maintains partnerships with academic institutions and clinical research organizations to advance its clinical programs. The company operates without marketed products and remains focused on advancing epetraborole through clinical development while exploring potential additional indications for its boron-based platform technology.